The Asia Pacific Age Related Macular Degeneration (AMD) Market would witness market growth of 6.4% CAGR during the forecast period (2023-2030).
The advancement of the market is aided by the increased incentives to pay for medications for age-related macular degeneration (AMD). A rise in the prevalence of eye problems is driving the \ market. A growing market trend, like the development of gene therapy for age-related macular degeneration, will lead to an increase in medical therapy for age-related macular degeneration.
Only a few medications, mostly anti-VEGFs, are now authorized to treat age-related macular degeneration. Frequent and unpleasant intraocular injections are required when using anti-VEGF drugs, which adds to the burden and results in non-adherence to therapy. Companies are working on longer-acting anti-VEGFs and vitreous implants that enable sustained medication delivery to overcome this obstacle. It is anticipated that the introduction of long-acting anti-VEGF medications like Beovu and Vabysmo will stimulate market expansion during the following years.
According to the National Library of Medicine, 81 patients (81 eyes) with dry AMD were included in Japan's survey of the condition. The mean age of the 81 patients was 76.6 8.4 years (range, 54-94), and 56 (69.1%) of them were men. 24 patients (29.5%) had a history of smoking. In 25 eyes (30.9%), the decimal best corrected-visual acuity (BCVA) was equal to or greater than 0.7, whereas, in 17 eyes (21.0%), it was less than 0.1. Of the 81 patients, dry AMD was found in 26 eyes (32.1%), neovascular AMD in 16 eyes (19.8%), and intermediate AMD in 18 eyes (22.2%) of those with the condition. The market is projected to expand as more individuals with AMD live in regional nations.
The China market dominated the Asia Pacific Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $849.1 million by 2030. The Japan market is registering a CAGR of 5.6% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.9% during (2023 - 2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Age Related Macular Degeneration (AMD) Market is Projected to reach USD 13.9 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F.Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 Asia Pacific Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 Asia Pacific Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 Asia Pacific Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 Asia Pacific Aflibercept Market by Country
5.2 Asia Pacific Ranibizumab Market by Country
5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 Asia Pacific Wet Market by Country
6.2 Asia Pacific Dry Market by Country
Chapter 7. Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 Asia Pacific Hospital Pharmacy Market by Country
7.2 Asia Pacific Retail Pharmacy Market by Country
7.3 Asia Pacific Online Pharmacy Market by Country
Chapter 8. Asia Pacific Age Related Macular Degeneration (AMD) Market by Country
8.1 China Age Related Macular Degeneration (AMD) Market
8.1.1 China Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 China Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 China Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 Japan Age Related Macular Degeneration (AMD) Market
8.2.1 Japan Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 Japan Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 India Age Related Macular Degeneration (AMD) Market
8.3.1 India Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 India Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 India Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 South Korea Age Related Macular Degeneration (AMD) Market
8.4.1 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.5 Singapore Age Related Macular Degeneration (AMD) Market
8.5.1 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type
8.5.2 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type
8.5.3 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.6 Malaysia Age Related Macular Degeneration (AMD) Market
8.6.1 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type
8.6.2 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type
8.6.3 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.7 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market
8.7.1 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
8.7.2 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
8.7.3 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
TABLE 1 Asia Pacific Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 3 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 4 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 5 Asia Pacific Aflibercept Market by Country, 2019 - 2022, USD Million
TABLE 6 Asia Pacific Aflibercept Market by Country, 2023 - 2030, USD Million
TABLE 7 Asia Pacific Ranibizumab Market by Country, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Ranibizumab Market by Country, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Wet Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Wet Market by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Dry Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Dry Market by Country, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
TABLE 27 China Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 28 China Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 29 China Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 30 China Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 31 China Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 32 China Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 33 China Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 China Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Japan Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 36 Japan Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 37 Japan Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 38 Japan Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 39 Japan Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 40 Japan Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 41 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 India Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 44 India Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 45 India Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 46 India Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 47 India Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 48 India Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 49 India Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 India Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 South Korea Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 52 South Korea Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 53 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 54 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 55 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 56 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 57 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Singapore Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 60 Singapore Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 61 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 62 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 63 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 64 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 65 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Malaysia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 68 Malaysia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 69 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 70 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 71 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 72 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 73 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 78 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 79 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 80 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 81 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Biogen, Inc.
TABLE 84 Key Information – Bayer AG
TABLE 85 Key Information – Apellis Pharmaceuticals, Inc.
TABLE 86 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 87 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 88 Key information – Ionis Pharmaceuticals, Inc.
TABLE 89 Key Information – Novartis AG
TABLE 90 Key Information – Sanofi S.A.
TABLE 91 Key Information – Coherus Biosciences, Inc.
TABLE 92 key information – Bausch Health Companies, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Age Related Macular Degeneration (AMD) Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Age Related Macular Degeneration (AMD)Market
FIG 4 Porter’s Five Forces Analysis – Age Related Macular Degeneration (AMD) Market
FIG 5 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Drug Type, 2022
FIG 6 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Drug Type, 2030
FIG 7 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2030, USD Million
FIG 8 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Disease Type, 2022
FIG 9 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Disease Type, 2030
FIG 10 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2030, USD Million
FIG 11 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2022
FIG 12 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2030
FIG 13 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Country, 2022
FIG 15 Asia Pacific Age Related Macular Degeneration (AMD) Market share by Country, 2030
FIG 16 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2030, USD Million
FIG 17 Swot Analysis: Biogen, Inc.
FIG 18 Swot Analysis: Bayer AG
FIG 19 Swot Analysis: Apellis Pharmaceuticals, Inc.
FIG 20 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 21 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 22 Swot Analysis: Ionis Pharmaceuticals, Inc.
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Sanofi S.A.
FIG 25 Swot Analysis: Coherus Biosciences, Inc.
FIG 26 Swot Analysis: Bausch Health Companies, Inc.